AD5
MCID: ALZ050
MIFTS: 46

Alzheimer Disease 5 (AD5)

Categories: Cardiovascular diseases, Genetic diseases, Mental diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Alzheimer Disease 5

MalaCards integrated aliases for Alzheimer Disease 5:

Name: Alzheimer Disease 5 58 12 74
Ad5 58 12
Alzheimer Disease, Familial, Type 5 13
Alzheimer Disease, Familial, 5 58
Alzheimer Disease, Familial 5 12
Alzheimer's Disease 5 12
Alzheimer Disease-5 58

Characteristics:

OMIM:

58
Inheritance:
autosomal dominant


HPO:

33
alzheimer disease 5:
Onset and clinical course late onset
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:0110037
OMIM 58 602096
ICD10 34 G30
MedGen 43 C1865868
SNOMED-CT via HPO 70 230267005 263681008 26929004
UMLS 74 C1865868

Summaries for Alzheimer Disease 5

Disease Ontology : 12 An Alzheimer's disease that is characterized by an associated with variation in the region 12p11.23-q13.12.

MalaCards based summary : Alzheimer Disease 5, also known as ad5, is related to alzheimer disease and perrault syndrome 1. An important gene associated with Alzheimer Disease 5 is AD5 (Alzheimer Disease 5), and among its related pathways/superpathways are Human T-cell leukemia virus 1 infection and Selenium Micronutrient Network. The drugs tannic acid and Benzocaine have been mentioned in the context of this disorder. Affiliated tissues include lung, breast and prostate, and related phenotypes are alzheimer disease and adipose tissue

Description from OMIM: 602096

Related Diseases for Alzheimer Disease 5

Graphical network of the top 20 diseases related to Alzheimer Disease 5:



Diseases related to Alzheimer Disease 5

Symptoms & Phenotypes for Alzheimer Disease 5

Human phenotypes related to Alzheimer Disease 5:

33
# Description HPO Frequency HPO Source Accession
1 alzheimer disease 33 HP:0002511

Symptoms via clinical synopsis from OMIM:

58
Neuro:
late-onset form of familial alzheimer disease (ad)

Misc:
onset at least 60 years

Clinical features from OMIM:

602096

MGI Mouse Phenotypes related to Alzheimer Disease 5:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 adipose tissue MP:0005375 8.8 ALOX5 HTR6 TP53

Drugs & Therapeutics for Alzheimer Disease 5

Drugs for Alzheimer Disease 5 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 105)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
tannic acid Approved Phase 3 1401-55-4
2
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
3 Mitogens Phase 2, Phase 3,Phase 3,Phase 1
4
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
5
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
6
Cisplatin Approved Phase 2,Phase 1 15663-27-1 441203 84093 2767
7
Nitroprusside Approved, Investigational Phase 1, Phase 2 15078-28-1 11963622
8
Flucytosine Approved, Investigational Phase 2,Phase 1 2022-85-7 3366
9
Doxorubicin Approved, Investigational Phase 2,Phase 1 23214-92-8 31703
10
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
11
Maraviroc Approved, Investigational Phase 2 376348-65-1 3002977
12
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
13
Coal tar Approved Phase 2 8007-45-2
14
leucovorin Approved Phase 1, Phase 2,Phase 2 58-05-9 6006 143
15
Capecitabine Approved, Investigational Phase 1, Phase 2,Phase 2 154361-50-9 60953
16
Necitumumab Approved, Investigational Phase 1, Phase 2 906805-06-9
17
Cetuximab Approved Phase 1, Phase 2,Phase 2 205923-56-4 56842117 2333
18
Fluorouracil Approved Phase 1, Phase 2,Phase 2 51-21-8 3385
19
Cyclophosphamide Approved, Investigational Phase 1, Phase 2,Phase 2 6055-19-2, 50-18-0 2907
20
Bevacizumab Approved, Investigational Phase 1, Phase 2,Phase 2 216974-75-3
21
Oxaliplatin Approved, Investigational Phase 1, Phase 2,Phase 2 61825-94-3 6857599 5310940 9887054 43805
22
Levoleucovorin Approved, Investigational Phase 1, Phase 2,Phase 2 68538-85-2
23
Gemcitabine Approved Phase 2 95058-81-4 60750
24
Sorafenib Approved, Investigational Phase 1, Phase 2 284461-73-0 216239 406563
25
Fulvestrant Approved, Investigational Phase 1, Phase 2,Phase 2 129453-61-8 104741 17756771
26
nivolumab Approved Phase 1, Phase 2,Phase 2 946414-94-4
27
Carboplatin Approved Phase 2 41575-94-4 38904 10339178 498142
28
rituximab Approved Phase 1, Phase 2 174722-31-7 10201696
29
carbamide peroxide Approved Phase 1, Phase 2 124-43-6
30
Calcium Approved, Nutraceutical Phase 1, Phase 2,Phase 2 7440-70-2 271
31
Glutamic Acid Approved, Nutraceutical Phase 1, Phase 2,Phase 2 56-86-0 33032
32
Doxil Approved June 1999 Phase 2,Phase 1 31703
33 Analgesics Phase 2
34 Antirheumatic Agents Phase 2,Phase 1
35 Analgesics, Non-Narcotic Phase 2
36 Peripheral Nervous System Agents Phase 2
37 Anti-Inflammatory Agents Phase 2
38 Cyclooxygenase Inhibitors Phase 2
39 Vaccines Phase 2,Phase 1
40 Cyclooxygenase 2 Inhibitors Phase 2
41 Anti-Inflammatory Agents, Non-Steroidal Phase 2
42 Angiogenesis Modulating Agents Phase 2,Phase 1
43 Angiogenesis Inhibitors Phase 2,Phase 1
44 Antineoplastic Agents, Phytogenic Phase 2,Phase 1
45 Endostatins Phase 2 71581480
46 Albumin-Bound Paclitaxel Phase 2,Phase 1
47 Antimitotic Agents Phase 2,Phase 1
48 Immunologic Factors Phase 1, Phase 2,Phase 2
49 Pharmaceutical Solutions Phase 1, Phase 2,Phase 2
50 Cola Phase 1, Phase 2

Interventional clinical trials:

(show top 50) (show all 99)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Intracoronary Ad5FGF-4 in Patients With Stable Angina Unknown status NCT00185263 Phase 2, Phase 3
2 Angiogenesis in Women With Angina Pectoris Who Are Not Candidates for Revascularization Unknown status NCT00438867 Phase 3
3 Ad5FGF-4 In Patients With Refractory Angina Due to Myocardial Ischemia Not yet recruiting NCT02928094 Phase 3
4 Efficacy and Safety of Intracoronary Ad5FGF-4 in Patients With Stable Angina (AGENT-3) Completed NCT00346437 Phase 2, Phase 3
5 Efficacy and Safety of Ad5FGF-4 for Myocardial Ischemia in Patients With Stable Angina Due to Coronary Artery Disease Terminated NCT01550614 Phase 3
6 AC6 Gene Transfer in Patients With Reduced Left Ventricular Ejection Fraction Heart Failure Not yet recruiting NCT03360448 Phase 3 Ad5.hAC6;Placebo
7 A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis Recruiting NCT03435081 Phase 3 Baricitinib;Placebo
8 A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis Enrolling by invitation NCT03559270 Phase 3 Baricitinib
9 Vaccine Therapy and Celecoxib in Treating Patients With Metastatic Nasopharyngeal Cancer Unknown status NCT00589186 Phase 2 celecoxib
10 Gene Therapy in Treating Patients With Recurrent Head and Neck Cancer Unknown status NCT00003257 Phase 2
11 Safety and Efficacy of DC-CIK in Patients With Advanced Non-Small-Cell Lung Cancer With Bone Metastases Unknown status NCT02688686 Phase 1, Phase 2
12 Trial of E10A in Head and Neck Cancer Unknown status NCT00634595 Phase 2 E10A;Cisplatin;Paclitaxel
13 Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA Completed NCT01147965 Phase 1, Phase 2
14 Use of Recombinant Adenovirus Therapy to Treat Localized Prostate Cancer Active, not recruiting NCT01931046 Phase 1, Phase 2 Ad5-SGE-REIC/Dkk3
15 Effectiveness of and Immune Response to HIV Vaccination Followed by Treatment Interruption in HIV Infected Patients Completed NCT00080106 Phase 2
16 QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer Active, not recruiting NCT03127098 Phase 1, Phase 2
17 Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or Pharynx Completed NCT00064103 Phase 1, Phase 2
18 AC6 Gene Transfer for CHF Completed NCT00787059 Phase 1, Phase 2 Ad5.hAC6;Sucrose (3%)
19 Investigation of V520 in a HIV Vaccine Dose Refinement Study (V520-027)(TERMINATED) Terminated NCT00350623 Phase 2
20 A Clinical Trial to Evaluate the Recombinant Human Type5 Adenovirus Vector Based Ebola Virus Disease Vaccine Completed NCT02575456 Phase 2
21 Phase 2b Study of GAM501 in the Treatment of Diabetic Ulcers of the Lower Extremities Completed NCT00493051 Phase 2
22 Randomized Trial of Suicide Gene Therapy and Prostate Cancer Completed NCT00583492 Phase 2
23 S0011, Gene Therapy & Surgery Followed by Chemo & RT in Newly Diagnosed Cancer of the Mouth or Throat Terminated NCT00017173 Phase 2 cisplatin
24 Chemotherapy Combined With Gene Therapy in Treating Patients Who Have Stage III or Stage IV Breast Cancer Completed NCT00044993 Phase 2 docetaxel;doxorubicin hydrochloride
25 Safety, Tolerability and Efficacy for CGF166 in Patients With Unilateral or Bilateral Severe-to-profound Hearing Loss Recruiting NCT02132130 Phase 1, Phase 2 CGF166
26 Study of Recombinant Adenovirus AdVince in Patients With Neuroendocrine Tumors; Safety and Efficacy Recruiting NCT02749331 Phase 1, Phase 2 AdVince
27 Investigation of V520 in an HIV Vaccine Proof-of-Concept Study (V520-023) Terminated NCT00095576 Phase 2 Comparator: placebo
28 Therapeutic Intensification Plus Immunomodulation to Decrease the HIV-1 Viral Reservoir Completed NCT00976404 Phase 2 ART intensification (raltegravir);ART intensification (maraviroc)
29 Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer Completed NCT01687244 Phase 2 INSTILADRIN
30 Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic Melanoma Patients Recruiting NCT03190824 Phase 2 OBP-301
31 Autologous SCT Followed by Dendritic Cell p53 Vaccination in Patients With Limited Stage Small Cell Lung Cancer Terminated NCT00776295 Phase 2
32 A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu Vaccine Completed NCT02918006 Phase 2
33 A Multicenter Randomized Double-blind Placebo-controlled Pilot Study of Safety, Pharmacodynamics and Efficacy of Different Treatments of Immunotherapeutic Drug Mobilan (M-VM3) in Patients With Diagnosed Prostate Cancer Active, not recruiting NCT02844699 Phase 1, Phase 2 Mobilan (M-VM3);Placebo
34 Safety and Efficacy of a Three-Dose Regimen of an Adenoviral HIV Vaccine (MRKAd5 HIV-1 Gag/Pol/Nef) in HIV Uninfected South African Adults Completed NCT00413725 Phase 2
35 A Double-blind Randomized Placebo-controlled Study of Safety and Immunogenicity of GamEvac-Lyo Completed NCT03333538 Phase 1, Phase 2
36 QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed Recruiting NCT03387111 Phase 1, Phase 2 Aldoxorubicin HCl;Avelumab;bevacizumab;Capecitabine;Cetuximab;Cisplatin;Cyclophosphamide;Fluorouracil;Leucovorin;nab-Paclitaxel;Necitumumab
37 QUILT-3.080: NANT Pancreatic Cancer Vaccine Recruiting NCT03586869 Phase 1, Phase 2 Aldoxorubicin HCl;Capecitabine;Cyclophosphamide;Fluorouracil;Leucovorin;nab-Paclitaxel;Oxaliplatin
38 QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine Recruiting NCT03563157 Phase 1, Phase 2 Avelumab;Capecitabine;Cetuximab;Cyclophosphamide;5-Fluorouracil;Leucovorin;Nab-paclitaxel;Oxaliplatin;Regorafenib
39 QUILT-3.088: NANT Pancreatic Cancer Vaccine Not yet recruiting NCT03563144 Phase 2 Gemcitabine;Nab-paclitaxel;Aldoxorubicin HCl;Avelumab;Bevacizumab;Capecitabine;Cyclophosphamide;5-Fluorouracil;Leucovorin;Oxaliplatin
40 QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine Recruiting NCT03563170 Phase 1, Phase 2 Capecitabine;Cyclophosphamide;5-Fluorouracil;Leucovorin;nab-Paclitaxel;Sorafenib;Cetuximab
41 QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. Recruiting NCT03387085 Phase 1, Phase 2 Aldoxorubicin HCl;Capecitabine;Cisplatin;Cyclophosphamide;Fluorouracil;Leucovorin;nab-Paclitaxel
42 QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy Not yet recruiting NCT03197571 Phase 1, Phase 2 capecitabine;cisplatin;cyclophosphamide;5Fluorouracil (5-FU);fulvestrant;leucovorin;nab-paclitaxel;Lovaza
43 QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC Not yet recruiting NCT03169777 Phase 1, Phase 2 capecitabine;Cyclophosphamide;5-Fluorouracil (5-FU);fulvestrant;leucovorin;nab paclitaxel;Lovaza;oxaliplatin
44 QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy Not yet recruiting NCT03169764 Phase 1, Phase 2 Capecitabine;Cisplatin;cyclophosphamide;5-Fluorouracil (5-FU);fulvestrant;leucovorin;nab-paclitaxel;Lovaza
45 QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors Not yet recruiting NCT03169738 Phase 1, Phase 2 Capecitabine;Cisplatin;cyclophosphamide;5-Fluorouracil (5-FU);fulvestrant;leucovorin;nab paclitaxel;Lovaza;Oxaliplatin
46 QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine Not yet recruiting NCT03554109 Phase 2 Leucovorin;5-Fluorouracil;Aldoxorubicin HCl;nab-Paclitaxel;Avelumab;Cyclophosphamide;Doxorubicin HCL;paclitaxel
47 QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy Not yet recruiting NCT03167177 Phase 1, Phase 2 Capecitabine;Cisplatin;Cyclophosphamide;5-fluorouracil;Leucovorin;nab-paclitaxel;omega-3-acid ethyl esters
48 QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy Not yet recruiting NCT03197584 Phase 1, Phase 2 Capecitabine;Cyclophosphamide;5-fluorouracil;Fulvestrant;Leucovorin;Paclitaxel;omega-3 acid ethyl esters;Oxaliplatin
49 NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy Not yet recruiting NCT03175666 Phase 1, Phase 2 capecitabine;cisplatin;cyclophosphamide;5-Fluorouracil;Leucovorin;nab-paclitaxel;Lovaza
50 QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer Not yet recruiting NCT03574649 Phase 2 Nab-paclitaxel;Cisplatin;5Fluorouracil;Cyclophosphamide;Aldoxorubicin;Avelumab;ALT-803;Docetaxel;carboplatin

Search NIH Clinical Center for Alzheimer Disease 5

Genetic Tests for Alzheimer Disease 5

Anatomical Context for Alzheimer Disease 5

MalaCards organs/tissues related to Alzheimer Disease 5:

42
Lung, Breast, Prostate, Liver, T Cells, Bone, Heart

Publications for Alzheimer Disease 5

Articles related to Alzheimer Disease 5:

(show top 50) (show all 164)
# Title Authors Year
1
Rodents Versus Pig Model for Assessing the Performance of Serotype Chimeric Ad5/3 Oncolytic Adenoviruses. ( 30744019 )
2019
2
The Novel Oncolytic Adenoviral Mutant Ad5-3Δ-A20T Retargeted to αvβ6 Integrins Efficiently Eliminates Pancreatic Cancer Cells. ( 29367266 )
2018
3
Ag85A-specific CD4+ T cell lines derived after boosting BCG-vaccinated cattle with Ad5-85A possess both mycobacterial growth inhibition and anti-inflammatory properties. ( 29655632 )
2018
4
Scavenger receptor-mediated Ad5 entry and acLDL accumulation in monocytes/macrophages synergistically trigger innate responses against viral infection. ( 29680370 )
2018
5
Long-term toxicity, pharmacokinetics and immune effects of a recombinant adenovirus vaccine expressing human papillomavirus 16 E6 and E7 proteins (HPV16 E6E7-Ad5 Vac) in primates. ( 29887967 )
2018
6
Establishing China's National Standard for the Recombinant Adenovirus Type 5 Vector-Based Ebola Vaccine (Ad5-EBOV) Virus Titer. ( 30381976 )
2018
7
Active and separate secretion of fiber and penton base during the early phase of Ad2 or Ad5 infection. ( 28264780 )
2017
8
Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia. ( 28152326 )
2017
9
Effects of metal ions on the structure and activity of a human anti-cyclin D1 single-chain variable fragment AD5. ( 28627625 )
2017
10
Open-label phase I clinical trial of Ad5-EBOV in Africans in China. ( 28708962 )
2017
11
A novel fiber chimeric conditionally replicative adenovirus-Ad5/F35 for tumor therapy. ( 29144842 )
2017
12
Combination of Adt-O1Manisa and Ad5-boIFNλ3 induces early protective immunity against foot-and-mouth disease in cattle. ( 27743960 )
2016
13
Interaction between hexon and L4-100K determines virus rescue and growth of hexon-chimeric recombinant Ad5 vectors. ( 26934960 )
2016
14
In vitro CRISPR-Cas9-mediated efficient Ad5 vector modification. ( 27125457 )
2016
15
A Plasmodium Promiscuous T Cell Epitope Delivered within the Ad5 Hexon Protein Enhances the Protective Efficacy of a Protein Based Malaria Vaccine. ( 27128437 )
2016
16
Efficacy of CD46-targeting chimeric Ad5/35 adenoviral gene therapy for colorectal cancers. ( 27203670 )
2016
17
Substitution of blood coagulation factor X-binding to Ad5 by position-specific PEGylation: Preventing vector clearance and preserving infectivity. ( 27302248 )
2016
18
A Recombinant Chimeric Ad5/3 Vector Expressing a Multistage Plasmodium Antigen Induces Protective Immunity in Mice Using Heterologous Prime-Boost Immunization Regimens. ( 27574299 )
2016
19
Prevalence of serum neutralizing antibodies to adenovirus type 5 (Ad5) and 41 (Ad41) in children is associated with age and sanitary conditions. ( 27682509 )
2016
20
Correction: Preclinical Assessment of FHIT Gene Replacement Therapy in Human Leukemia Using a Chimeric Adenovirus, Ad5/F35. ( 27856602 )
2016
21
Potent antitumor activity of the Ad5/11 chimeric oncolytic adenovirus combined with interleukin-24 for acute myeloid leukemia via induction of apoptosis. ( 25339149 )
2015
22
Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy. ( 25714011 )
2015
23
Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer. ( 25956394 )
2015
24
Efficient genome editing in hematopoietic stem cells with helper-dependent Ad5/35 vectors expressing site-specific endonucleases under microRNA regulation. ( 26052525 )
2015
25
Overexpression of Ad5 precursor terminal protein accelerates recombinant adenovirus packaging and amplification in HEK-293 packaging cells. ( 24784448 )
2014
26
Ad5/48 hexon oncolytic virus expressing sTGFβRIIFc produces reduced hepatic and systemic toxicities and inhibits prostate cancer bone metastases. ( 24791939 )
2014
27
Hexon hypervariable region-modified adenovirus type 5 (Ad5) vectors display reduced hepatotoxicity but induce T lymphocyte phenotypes similar to Ad5 vectors. ( 24943382 )
2014
28
Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef vaccine induced immune responses. ( 25090110 )
2014
29
CpG-mediated modulation of MDSC contributes to the efficacy of Ad5-TRAIL therapy against renal cell carcinoma. ( 25143233 )
2014
30
Preferential infection of human Ad5-specific CD4 T cells by HIV in Ad5 naturally exposed and recombinant Ad5-HIV vaccinated individuals. ( 25197078 )
2014
31
Evaluation of novel large cut-off ultrafiltration membranes for adenovirus serotype 5 (Ad5) concentration. ( 25546428 )
2014
32
The effect of artificial lipid envelopment of Adenovirus 5 (Ad5) on liver de-targeting and hepatotoxicity. ( 23146432 )
2013
33
Alternative serotype adenovirus vaccine vectors elicit memory T cells with enhanced anamnestic capacity compared to Ad5 vectors. ( 23152535 )
2013
34
The effectiveness of the oncolytic activity induced by Ad5/F35 adenoviral vector is dependent on the cumulative cellular conditions of survival and autophagy. ( 23403990 )
2013
35
Killing effect of Ad5/F35-APE1 siRNA recombinant adenovirus in combination with hematoporphrphyrin derivative-mediated photodynamic therapy on human nonsmall cell lung cancer. ( 23509821 )
2013
36
Combined use of adenoviral vector Ad5/F35-mediated APE1 siRNA enhances the therapeutic efficacy of adenoviral-mediated p53 gene transfer in hepatoma cells in vitro and in vivo. ( 23563597 )
2013
37
A phase I clinical trial of Ad5/3-Δ24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer. ( 23756180 )
2013
38
Gene therapy for cancer through adenovirus vector‑mediated expression of the Ad5 early region gene 1A based on loss of IGF2 imprinting. ( 23900345 )
2013
39
Chimeric adenoviral vector Ad5F35L containing the Ad5 natural long-shaft exhibits efficient gene transfer into human T lymphocytes. ( 23933078 )
2013
40
Expression and purification of a human anti-cyclin D1 single-chain variable fragment antibody AD5 and its characterization. ( 24127128 )
2013
41
Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors. ( 21630267 )
2012
42
HPV-16 E1, E2 and E6 each complement the Ad5 helper gene set, increasing rAAV2 and wt AAV2 production. ( 21850053 )
2012
43
Syrian hamster tumor model to study oncolytic Ad5-based vectors. ( 21948468 )
2012
44
A fiber chimeric CRAd vector Ad5/11-D24 double-armed with TRAIL and arresten for enhanced glioblastoma therapy. ( 22136065 )
2012
45
Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine. ( 22156519 )
2012
46
Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine. ( 22201684 )
2012
47
Suppression of protein phosphatase 2A activity enhances Ad5/F35 adenovirus transduction efficiency in normal human B lymphocytes and in Raji cells. ( 22210093 )
2012
48
An optimized SIV DNA vaccine can serve as a boost for Ad5 and provide partial protection from a high-dose SIVmac251 challenge. ( 22406458 )
2012
49
Modification of Ad5 hexon hypervariable regions circumvents pre-existing Ad5 neutralizing antibodies and induces protective immune responses. ( 22496772 )
2012
50
Decreased pre-existing Ad5 capsid and Ad35 neutralizing antibodies increase HIV-1 infection risk in the Step trial independent of vaccination. ( 22496775 )
2012

Variations for Alzheimer Disease 5

Expression for Alzheimer Disease 5

Search GEO for disease gene expression data for Alzheimer Disease 5.

Pathways for Alzheimer Disease 5

Pathways related to Alzheimer Disease 5 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.66 TP53 TSPO
2
Show member pathways
11.59 ALOX5 TP53
3 11.26 ALOX5 TSPO
4 11.02 ALOX5 HTR6
5 10.68 ALOX5 TP53

GO Terms for Alzheimer Disease 5

Cellular components related to Alzheimer Disease 5 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nuclear matrix GO:0016363 8.62 ALOX5 TP53

Biological processes related to Alzheimer Disease 5 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of reactive oxygen species metabolic process GO:2000379 8.62 TP53 TSPO

Sources for Alzheimer Disease 5

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....